54 search results for: mechanism of disease

European Academy <b>of</b> Allergy and Clinical Immunology (EAACI) 2023 | Hamburg
Congress
9
June
2023
Congress
European Academy of Allergy and Clinical Immunology (EAACI) 2023 | Hamburg

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.

.
Congress
1
December
2023
Congress
Global ADVENT FORUM 2023, Dermatology Section | Madrid

New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.

Differential Effects <b>of</b> Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
Dermatology
Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.

View more
KOL Video Interview – Dr Paula Luna
Dermatology
KOL Video Interview – Dr Paula Luna
expert video

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.

View more
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
Dermatology
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson outlines why early, targeted control of type 2 inflammation may modify the course of atopic dermatitis by addressing upstream drivers of barrier dysfunction, dysbiosis, and itch.

View more
Charting the Future: Preventing the Atopic March
Dermatology
Charting the Future: Preventing the Atopic March
expert video

In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.

View more
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
Dermatology
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
expert video

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

View more
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
Dermatology
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
slide presentation

This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

View more